Merck Sharp and Dohme has reported positive data from a new long-term clinical study of Isentress, its approved treatment for HIV-1 infection among adult patients.
Final results from the STARTMRK trial have demonstrated that the compound is able to deliver efficacy, safety and tolerability for previously untreated adult patients with HIV-1 for up to 240 weeks.
At all pre-specified time points, the regimen containing Isentress had fewer drug-related adverse events versus the comparison group, while generating better viral suppression and a greater immunologic response.
Dr Daria Hazuda, worldwide head of antiviral basic research at Merck Sharp and Dohme and lead scientist for Isentress, said: "After more than 25 years of leadership in HIV research, we remain dedicated to conducting comprehensive research to help address the real-world needs of people living with HIV."
This comes after the firm presented encouraging data from clinical and preclinical Alzheimer's drug trials at the Alzheimer's Association International Conference last week.See all the latest jobs in Pharmaceutical